PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30481547-6	2019	These findings suggest that NAbs-alpha-syn overcomes the deficiency of IVIG and exhibits a promising therapeutic potential for the treatment of PD.	nabs	28-32	synuclein, alpha	Mus musculus	33-42	
30481547-4	2019	Our further investigation results showed that NAbs-alpha-syn inhibited alpha-syn aggregation and attenuated alpha-syn-induced cytotoxicity in vitro.	nabs	46-50	synuclein, alpha	Mus musculus	51-60	
30481547-4	2019	Our further investigation results showed that NAbs-alpha-syn inhibited alpha-syn aggregation and attenuated alpha-syn-induced cytotoxicity in vitro.	nabs	46-50	synuclein, alpha	Mus musculus	71-80	
30481547-4	2019	Our further investigation results showed that NAbs-alpha-syn inhibited alpha-syn aggregation and attenuated alpha-syn-induced cytotoxicity in vitro.	nabs	46-50	synuclein, alpha	Mus musculus	71-80